Clinical trials: Complementary Therapies
Rett Syndrome
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.
- Trial name
- ASPIRE (NCT07480564)
- Testing
- TSHA-102
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Taysha Gene Therapies, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study…
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Long COVID
- Trial name
- NCT05601180
- Testing
- Respicure®, Standard of care
- Where
- 8 sites in Algeria
- Volunteers
- 402 people
- Sponsor
- Beker Laboratories
Attention Deficit Hyperactivity Disorder
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
This study tests the effects of an investigational antipsychotic drug (called OPC-34712) in adults with attention deficit hyperactivity disorder (ADHD) when taken with an approved stimulant medication to explore a possible impact…
- Trial name
- STEP-A (NCT01074294)
- Testing
- OPDC-34712, Stimulant Therapy
- Where
- 35 sites in United States
- Volunteers
- 740 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
CLN3, Batten Disease
Gene Therapy for Children With CLN3 Batten Disease
This is a phase 1/2, open-label, single dose, dose-escalation clinical trial to evaluate the safety and efficacy of CLN-301 (previous NCH Code: scAAV9.P546.CLN3) delivered intrathecally into the lumbar spinal cord region of…
- Trial name
- NCT03770572
- Testing
- Low dose CLN-301, High dose CLN-301
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Neela Therapeutics
Quality of Life, Fatigue
Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
The objective of this study is to evaluate the efficacy and safety of PG2 as a complementary treatment to conventional chemotherapy among NSCLC patients.
- Conditions
- Quality of Life, Fatigue, Complementary
- Trial name
- NCT00518869
- Testing
- PG2
- Where
- 10 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- PhytoHealth Corporation
Covid19
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
Phase 2b clinical trial to evaluate the safety and efficacy of intranasal application of GX-03 as a treatment and prevention for COVID-19.
- Trial name
- NCT04951349
- Testing
- GX-03, Petrolatum ointment
- Where
- 3 sites in Panama
- Volunteers
- 85 people
- Sponsor
- Turn Therapeutics
Pregnancy, Migraine
External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women.
- Conditions
- Pregnancy, Migraine, Headache, Postpartum
- Trial name
- NCT06788977
- Testing
- external Trigeminal Nerve Stimulation
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Cefaly Technology
Mild Knee Osteoarthritis
Tregocel® as a Dietary Supplement in Mild Knee Osteoarthritis
This study is an assessment of the overall performance of participants with symptomatic mild knee OA taking Tregocel® as a dietary supplement in addition to standard of care treatment.
- Trial name
- NCT03636035
- Testing
- Tregocel®
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Max Biocare Pty. Ltd.
Gastroenterology
A Randomized Clinical Trial of Shenbai Granules in Reducing Recurrence of Colorectal Adenoma
This study evaluates Shenbai Granules in Prevention of Colorectal Adenomatous Polyp Recurrence After Colonoscopy.Half of participants will receive Shenbai Granules,while the other half will receive a placebo.
- Trial name
- NCT03616444
- Testing
- Shenbai Granules
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
Asthma
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.
- Trial name
- STAR (NCT00445107)
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 8 Weeks
- Volunteers
- 198 people
- Sponsor
- Organon and Co
Herpes Zoster, Neuralgia
An Open-Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain
This study is an open-label, multicenter, extension study for subjects who completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7days) before entry into Study C114
- Conditions
- Herpes Zoster, Neuralgia, Pain, HIV Infections
- Trial name
- NCT00089557
- Testing
- Capsaicin Dermal Patch
- Sponsor
- NeurogesX
Chronic Pain
Optimizing Patient Engagement in a Novel Pain Management Initiative (OPEN)
The OPEN study has two aims: The first is to identify what helps to keep patients involved with a Medicaid chronic pain management program and to identify features of an ideal text-message-based program for people enrolled in the…
- Trial name
- OPENtext (NCT02136108)
- Testing
- OPENtext, OPENnav
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Inflexxion, Inc.
HIV Infections
A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial
The objective of this study is to determine the long term safety and tolerability of an additional infusion of 10 billion VRX496 gene-modified CD4 T cells with a focus on evaluating additional therapeutic benefits with respect to…
- Trial name
- Rollover (NCT00622232)
- Testing
- VRX496-transduced autologous CD4 T cells
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- VIRxSYS Corporation
Diabetes, Type I
A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes
Purpose: The purpose of the trial is to assess the safety profile of the study treatment and to evaluate its efficacy in terms of improvement in key diabetes management parameters, including insulin requirements and β-cell…
- Trial name
- IMMUNOSTEM (NCT06938334)
- Testing
- Autologous CD34+ cell enriched population containing HSPCs transduced ex vivo using a LVV encoding the hPD-L1 DNA
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Altheia Science
Herpes Zoster, Neuralgia
Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products.
- Conditions
- Herpes Zoster, Neuralgia, Pain, HIV Infections
- Trial name
- NCT00082316
- Testing
- Capsaicin Dermal Patch
- Where
- 17 sites in United States
- Sponsor
- NeurogesX
HIV Infections, Peripheral Nervous System Diseases
Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful HIV-associated neuropathy.
- Conditions
- HIV Infections, Peripheral Nervous System Diseases, Pain
- Trial name
- NCT00085761
- Testing
- Capsaicin Dermal Patch
- Where
- 2 sites in United States
- Sponsor
- NeurogesX
Rett Syndrome
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
The primary objectives of this study are to evaluate the safety of a single intrathecal (IT) dose of TSHA-102 in females with typical Rett syndrome, to select the TSHA-102 dose with the best benefit/risk profile based on the…
- Trial name
- NCT05606614
- Testing
- TSHA-102
- Where
- 9 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Taysha Gene Therapies, Inc.